Join our daily newsletter At The Bell to receive exclusive market insights
- AdAlta (1AD) has administered the first three doses of its AD-214 lead candidate to a cohort of healthy volunteers in a phase one clinical trial
- Eight participants received either five milligrams per kilogram of AD-214 or a placebo in part B of the trial, reporting no dose-limiting adverse events
- AD1 is developing the drug to treat idiopathic pulmonary fibrosis, other fibrotic diseases and potentially cancers for which existing therapies are sub-optimal
- The company expects to complete part B of the trial by the end of the year with the resulting data set to support phase two clinical trial applications in 2022
- AdAlta shares last traded at 16.5 cents each
Clinical-stage drug developer AdAlta (1AD) has administered the first three doses of its AD-214 lead candidate to a cohort of healthy volunteers in a phase one clinical trial.
Eight participants received either five milligrams per kilogram of AD-214 or a placebo in part B of the trial, reporting no dose-limiting adverse events.
AD1 is developing the drug to treat idiopathic pulmonary fibrosis, other fibrotic diseases and potentially cancers, for which existing therapies are sub-optimal.
AdAlta Vice President of Clinical Product Development Dr Claudia Gregorio-King said the company is pleased to progress into the multiple-dose part of its evaluation.
“The excellent safety profile and high receptor occupancy observed in the single-dose part A of our study facilitated rapid ethics approval of part B of the phase one program,” Dr Gregorio-King said.
“We also remain on track to begin our multi-dose study in interstitial lung disease patients in the third quarter of 2021,” she added.
“We continue to express our gratitude to the volunteers who have agreed to participate in our study and help advance a potential new therapy for patients battling idiopathic pulmonary fibrosis and other interstitial lung diseases.”
The company expects to complete part B of the trial by the end of the year with the phase one data set to support phase two clinical trial applications in 2022.
AdAlta shares are in the grey, last trading at 16.5 cents each at 10:04 am AEST.
